F-Star Therapeutics Inc
NASDAQ:FSTX
Net Margin
F-Star Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | US |
Market Cap | 156.5m USD |
Net Margin |
-211%
|
Country | US |
Market Cap | 288.9B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 168.6B USD |
Net Margin |
13%
|
Country | US |
Market Cap | 113B USD |
Net Margin |
37%
|
Country | US |
Market Cap | 106.9B USD |
Net Margin |
29%
|
Country | AU |
Market Cap | 138.6B AUD |
Net Margin |
17%
|
Country | US |
Market Cap | 84.5B USD |
Net Margin |
2%
|
Country | US |
Market Cap | 50.6B USD |
Net Margin |
-116%
|
Country | US |
Market Cap | 43.1B USD |
Net Margin |
-33%
|
Country | US |
Market Cap | 33.5B USD |
Net Margin |
12%
|
Country | KR |
Market Cap | 40T KRW |
Net Margin |
25%
|
Profitability Report
View the profitability report to see the full profitability analysis for F-Star Therapeutics Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on F-Star Therapeutics Inc's most recent financial statements, the company has Net Margin of -211.3%.